×
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
NASDAQ:RNA

Avidity Biosciences Stock Forecast, Price & News

$14.48
-0.07 (-0.48%)
(As of 06/28/2022 11:10 AM ET)
Add
Compare
Today's Range
$14.32
$14.77
50-Day Range
$11.18
$18.28
52-Week Range
$10.89
$29.59
Volume
822 shs
Average Volume
489,295 shs
Market Capitalization
$720.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.50
30 days | 90 days | 365 days | Advanced Chart

Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Stock Forecast (MarketRank)

Overall MarketRank

2.03 out of 5 stars

Medical Sector

569th out of 1,436 stocks

Pharmaceutical Preparations Industry

255th out of 687 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
Avidity Biosciences logo

About Avidity Biosciences (NASDAQ:RNA)

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

RNA Stock News Headlines

Avidity Biosciences (NASDAQ:RNA) Stock Price Down 8.2%
Avidity Biosciences (NASDAQ:RNA) Shares Gap Up to $12.65
Avidity Biosciences: Q4 Earnings Insights
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
125
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/28/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$49.50
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+241.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-118.01 million
Net Margins
-1,525.48%
Pretax Margin
-1,525.48%

Debt

Sales & Book Value

Annual Sales
$9.33 million
Book Value
$8.13 per share

Miscellaneous

Free Float
41,761,000
Market Cap
$720.52 million
Optionable
Not Optionable
Beta
1.35














Avidity Biosciences Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Avidity Biosciences stock.
View analyst ratings for Avidity Biosciences
or view top-rated stocks.

What is Avidity Biosciences' stock price forecast for 2022?

4 analysts have issued 12 month price objectives for Avidity Biosciences' shares. Their RNA stock forecasts range from $36.00 to $59.00. On average, they anticipate Avidity Biosciences' share price to reach $49.50 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price.
View analysts' price targets for Avidity Biosciences
or view top-rated stocks among Wall Street analysts.

How has Avidity Biosciences' stock price performed in 2022?

Avidity Biosciences' stock was trading at $23.77 on January 1st, 2022. Since then, RNA stock has decreased by 39.1% and is now trading at $14.48.
View the best growth stocks for 2022 here
.

When is Avidity Biosciences' next earnings date?

Avidity Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Avidity Biosciences
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) issued its earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.23. The biotechnology company had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.50 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 36.26% and a negative net margin of 1,525.48%.
View Avidity Biosciences' earnings history
.

Who are Avidity Biosciences' key executives?

Avidity Biosciences' management team includes the following people:
  • Dr. Troy Edward Wilson J.D., Ph.D., Co-Founder & Chairman (Age 53, Pay $65k)
  • Ms. Sarah Boyce, Pres, CEO & Director (Age 50, Pay $1M)
  • Mr. Michael F. MacLean, CFO & Chief Bus. Officer (Age 56, Pay $650.38k)
  • Dr. W. Michael Flanagan Ph.D., Chief Technical Officer (Age 60, Pay $1M)
  • Dr. Arthur A. Levin Ph.D., Chief Scientific Officer (Age 68, Pay $662.86k)
  • Mr. Joseph T. Baroldi, Consultant (Age 43, Pay $642.43k)
  • Prof. Mark E. Davis, Scientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.s
  • Dr. Frank McCormick Ph.D., Scientific Founder & Member of Scientific Advisory Board (Age 72)
  • Ms. Kathleen Gallagher, Sr. VP of Corp. Communications & Investor Relations
  • Dr. John W. Wallen III, VP of Intellectual Property, Gen. Counsel & Sec. (Age 64)

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

(RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Aaron Wealth Advisors LLC (8.01%), BlackRock Inc. (6.56%), Vanguard Group Inc. (4.62%), RA Capital Management L.P. (4.36%), State Street Corp (3.30%) and Wellington Management Group LLP (2.28%). Company insiders that own Avidity Biosciences stock include Arthur A Levin and Rtw Investments, Lp.
View institutional ownership trends for Avidity Biosciences
.

Which major investors are selling Avidity Biosciences stock?

RNA stock was sold by a variety of institutional investors in the last quarter, including US Bancorp DE, Bank of America Corp DE, Citigroup Inc., BlackRock Inc., Harbor Capital Advisors Inc., JPMorgan Chase & Co., Metropolitan Life Insurance Co NY, and Northern Trust Corp.
View insider buying and selling activity for Avidity Biosciences
or view top insider-selling stocks.

Which major investors are buying Avidity Biosciences stock?

RNA stock was acquired by a variety of institutional investors in the last quarter, including Aaron Wealth Advisors LLC, RA Capital Management L.P., Vanguard Group Inc., State Street Corp, Dimensional Fund Advisors LP, Walleye Capital LLC, Walleye Capital LLC, and Wellington Management Group LLP.
View insider buying and selling activity for Avidity Biosciences
or or view top insider-buying stocks.

How do I buy shares of Avidity Biosciences?

Shares of RNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avidity Biosciences' stock price today?

One share of RNA stock can currently be purchased for approximately $14.48.

How much money does Avidity Biosciences make?

Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $720.52 million and generates $9.33 million in revenue each year. The biotechnology company earns $-118.01 million in net income (profit) each year or ($2.910010) on an earnings per share basis.

How many employees does Avidity Biosciences have?

Avidity Biosciences employs 125 workers across the globe.

How can I contact Avidity Biosciences?

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for Avidity Biosciences is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at [email protected].

This page (NASDAQ:RNA) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.